Parabilis Medicines
About Parabilis Medicines
Parabilis Medicines is a biopharmaceutical company focused on developing ultra-tunable peptide therapeutics to address cancer and other diseases with high unmet need. The company emphasizes a research-driven approach, aiming to deploy a novel modality to achieve transformative patient outcomes. Its communications highlight a strategic focus on innovation and science-driven programs, including clinical exploration of its medicines. While the exact geographic headquarters aren’t stated in the available content, Parabilis presents itself as a dedicated biotech entity advancing next-generation peptide medicines.
Recent News
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
Tuneable Peptide Biotech Parabilis Files IPO
Regeneron Inks a ~$2.3B Deal with Parabilis Medicines to Advance Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
Parabilis Reveals IPO Plans the Day After Regeneron Deal as Listings Heat Up
Regeneron Reaches $125M Parabilis Deal for Hard-to-Catch Drug Targets
Parabilis’ Path From POC to New Indications and Challenging Targets
The Week’s 10 Biggest Funding Rounds: XAI Leads As 2026 Is Off To A Brisk Start
Høeg Fired in Latest FDA Shakeup; 20 People Die After Taking Amgen Drug
The BioPharm Brief: ADC Expansion, Early Breast Cancer, Biosimilar Momentum
Regeneron, Parabilis Set Out to Create New Drug Class in Deal Worth up to $2.3B
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive Β-Catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors
The Biggest Biotech Funding Rounds in January 2026
Who’s Winning Pharma’s Innovation Race? The Rankings Are Out.
Parabilis Gets $305M to Tackle ‘Undruggable’ Proteins
Recent Deals
Parabilis Medicines Secures $305M Series F Funding Led by RA Capital, Fidelity Management, and Janus Henderson
Regeneron, Parabilis Set Out to Create New Drug Class in Deal Worth up to $2.3B
Parabilis Medicines Announces Plans for IPO
Parabilis Medicines Raises $305M to Tackle Undruggable Proteins
Parabilis Secures $305M Crossover Round to Advance Helicon Platform